CARLSBAD, Calif.–(BUSINESS THREAD)–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX ), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its second quarter 2022 financial and operating results on Thursday August 11, 2022, after the close of US financial markets. Lineage Management will also host a conference call and webcast on Thursday, August 11, 2022 at 4:30 PM ET/1:30 PM PT to discuss second quarter financial and operating results of 2022 and to provide a commercial update.
Interested parties may access the conference call by dialing (800) 715-9871 from the US and Canada and (646) 307-1952 from outside the US and Canada and should request the “Lineage Cell Therapy Call” or provide the conference ID number 6448886. A live webcast of the conference will be available online at investors section of the Lineage website. A replay of the webcast will be available on Lineage’s website for 30 days and a telephone replay will be available until August 18, 2022 by dialing (800) 770-2030 from the US and Canada and entering conference id 6448886.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. Using this platform, Lineage develops and manufactures terminally differentiated specialized human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or are administered as a means of helping the body mount an effective immune response to cancer Lineage’s clinical programs are in billion dollar opportunity markets and include five allogeneic (“available”) product candidates: (i) OpRegen, a retinal pigment epithelial cell therapy in development for phase 1/2a for the treatment of geographic atrophy secondary to age-related macular degeneration, which is being developed under a global collaboration with Roche and Genentech, a member of the Roche Group; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injury; (iii) VAC2, a dendritic cell therapy produced from Lineage’s VAC technology platform for immuno-oncology and infectious diseases, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer small (iv) ANP1, an auditory neural progenitor cell therapy for the potential treatment of auditory neuropathy, and (v) PNC1, a photoreceptor neural cell therapy for the treatment of vision loss due to dysfunction or photoreceptor damage. For more information, visit www.lineagecell.com or follow the company on Twitter @LineageCell.